Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. (September 2019)

• Record Type: Journal Article
• Authors: Dufort, Sandrine; Appelboom, Geoffrey; Verry, Camille; Barbier, Emmanuel L; Lux, François; Bräuer-Krisch, Elke; Sancey, Lucie; Chang, Steven D.; Zhang, Michael; Roux, Stéphane; Tillement, Olivier; Le Duc, Géraldine
• Is Part Of: Journal of clinical neuroscience. Volume 67(2019)
• Page Start: 215
• Page End: 219
• Publication Date: 2019-09
• Subjects: Glioblastoma -- Temozolomide -- Theranostic -- Nanoparticles -- Radiosensitizers -- Chemoradiation; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.05.065
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Ultrasmall theranostic nanoparticles rapidly distribute (<1 h) to target glioma. MRI contrast enhancement can be sustained at 24 h after administration. These nanoparticles exhibit potential chemotherapy and radiation sensitization. Abstract: We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model. The 9L glioma cells were orthotopically implanted in 10-week-old Fischer rats. The intra-tumoral accumulation of AGuIX was quantified using MRI T1-maps. Rats randomized to intervention cohorts were subsequently treated with daily temozolomide for five consecutive days before radiotherapy treatment. Collectively, a series of 32 rats were divided into untreated (n = 7), temozolomide-only (n = 7), temozolomide and MRT (n = 9), AGuIX and MRT (n = 7), and triple therapy (temozolomide, AGuIX NPs, and MRT; n = 9) cohorts. AGuIX nanoparticles achieved a maximum intra-tumoral concentration (expressed as concentration of Gd3+) at 1 h after intravenous injection, reaching a mean of 227.9 ± 60 μM. This was compared to concentrations of 10.5 ± 9.2 μM and 62.9 ± 24.7 μM in the contralateral hemisphere and cheek, respectively. There was a slower washout in the intra-tumor region, with sustained tumor-to-contralateral ratio of AGuIX, up to 14-fold, for each time point. The combination of AGuIX or temozolomide with MRT improved the median survival time (40 days) compared to the MeST of control rats (25 days) (p < 0.002). There was a trend towards further increased survival when the three treatments were combined (MeST of 46 days). This study demonstrated the selective accumulation of AGuIX in high grade glioma, as well as the potential survival benefits when combined with chemoradiation.